Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 601–650 of 847 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT03036046	Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml…(SAFEGUARDFP)	Phase 1 / Phase 2	withdrawn	Jan 30, 2017	F2G Ltd	Study no longer required	Other (stated, no rule matched)
NCT02335814	First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid…	Phase 1	terminated	Jan 12, 2015	RAPT Therapeutics, Inc.	Dose escalation completed; Sponsor decision	Sponsor / business decision
NCT01564277	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	Phase 2	terminated	Mar 27, 2012	Roswell Park Cancer Institute	low accrual	Enrollment / accrual
NCT00583102	Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory…	Phase 1 / Phase 2	terminated	Dec 31, 2007	University of Iowa	Slow accrual, PI left institution	Investigator
NCT01442714	Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk…	Phase 2	terminated	Sep 28, 2011	Stanford University	Lack of efficacy - Inability to meet the primary response endpoint	Efficacy / futility
NCT00295880	Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating…	Phase 1 / Phase 2	terminated	Feb 24, 2006	Masonic Cancer Center, University of Minnesota	Time to engraftment would not be improved compared to historical controls.	Other (stated, no rule matched)
NCT00354172	Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood…	Phase 2	terminated	Jul 20, 2006	Masonic Cancer Center, University of Minnesota	Competing study was started.	Other (stated, no rule matched)
NCT00392782	Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease	Phase 2	terminated	Oct 26, 2006	Masonic Cancer Center, University of Minnesota	not stated	Not stated
NCT00602446	Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell…	Phase 2	terminated	Jan 28, 2008	Masonic Cancer Center, University of Minnesota	Due to slow accrual of patients	Enrollment / accrual
NCT00818649	Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or…	Phase 2	terminated	Jan 8, 2009	Masonic Cancer Center, University of Minnesota	Met protocol stop rule \[i.e., extreme toxicity\]	Safety / toxicity
NCT00963872	Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and…	Phase 1 / Phase 2	terminated	Aug 24, 2009	Masonic Cancer Center, University of Minnesota	Lack of efficacy after interim analysis	Efficacy / futility
NCT01464359	T-Cell Depleted Double UCB for Refractory AML	Phase 2	terminated	Nov 3, 2011	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT02049801	MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or…	Phase 1	terminated	Jan 30, 2014	Bruno C. Medeiros	logistics	Other (stated, no rule matched)
NCT00176839	Stem Cell Transplantation for Hematological Malignancies	Phase 2 / Phase 3	terminated	Sep 15, 2005	Masonic Cancer Center, University of Minnesota	Replaced by a different study	Other (stated, no rule matched)
NCT01207076	AHN-12 Biodistribution in Advanced Leukemia	Phase 1	terminated	Sep 22, 2010	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT01343368	Preservation of Ovarian Function After Hematopoietic Cell Transplant	Phase 2	terminated	Apr 28, 2011	Masonic Cancer Center, University of Minnesota	not stated	Not stated
NCT02765997	StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies	Phase 2	withdrawn	May 9, 2016	Masonic Cancer Center, University of Minnesota	IRB Disapproval	Other (stated, no rule matched)
NCT00376519	Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood…	Phase 1	terminated	Sep 15, 2006	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in…	Phase 1 / Phase 2	withdrawn	Jul 15, 2010	Masonic Cancer Center, University of Minnesota	Replaced by a new study	Other (stated, no rule matched)
NCT01639456	CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell…	Phase 2	withdrawn	Jul 12, 2012	Masonic Cancer Center, University of Minnesota	study was abandoned and a new study was written to replace this one	Other (stated, no rule matched)
NCT01677949	Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute…	Phase 2	withdrawn	Sep 3, 2012	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT00290628	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A	terminated	Feb 13, 2006	Masonic Cancer Center, University of Minnesota	Replaced with another study	Other (stated, no rule matched)
NCT00618696	Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced…	Phase 1	terminated	Feb 20, 2008	Masonic Cancer Center, University of Minnesota	Replaced with another study	Other (stated, no rule matched)
NCT00725062	Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor…	Phase 1	terminated	Jul 30, 2008	Masonic Cancer Center, University of Minnesota	Slow accrual.	Enrollment / accrual
NCT03108911	Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia…	Phase 2	terminated	Apr 11, 2017	Rutgers, The State University of New Jersey	limited resources	Other (stated, no rule matched)
NCT02433483	Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger…	Phase 2	terminated	May 5, 2015	St. Jude Children's Research Hospital	The study was closed due to poor accrual and because of competing protocols.	Enrollment / accrual
NCT00101140	Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission	Phase 2	withdrawn	Jan 10, 2005	Eastern Cooperative Oncology Group	not stated	Not stated
NCT00281879	Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With…	Phase 2	terminated	Jan 25, 2006	OHSU Knight Cancer Institute	not stated	Not stated
NCT03138395	iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML(iCare3)	—	withdrawn	May 3, 2017	University of Florida	Study design modified to collect specimens from a bank requiring a separate IRB-approved protocol.	Other (stated, no rule matched)
NCT02255162	Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML	Phase 1	terminated	Oct 2, 2014	Massachusetts General Hospital	Slow Accrual	Enrollment / accrual
NCT01085656	A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS	Phase 1	terminated	Mar 12, 2010	University of Florida	not stated	Not stated
NCT01034592	Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent…	Phase 1	terminated	Dec 17, 2009	Jason Robert Gotlib	Poor accrual related to rarity of Diamond-Blackfan anemia (DBA)	Enrollment / accrual
NCT01342887	Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating…	Phase 1 / Phase 2	terminated	Apr 27, 2011	Fred Hutchinson Cancer Center	not stated	Not stated
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A…	N/A	terminated	Feb 26, 2010	Fred Hutchinson Cancer Center	Funding withdrawal	Funding
NCT00538980	Dasatinib in Polycythemia Vera	Phase 2	terminated	Oct 3, 2007	Weill Medical College of Cornell University	This study was terminated due to lack of efficacy.	Efficacy / futility
NCT00719849	Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological…	Phase 2	terminated	Jul 22, 2008	Fred Hutchinson Cancer Center	A new protocol was developed to replace this protocol in 2008, with removal of ATG and extension of…	Other (stated, no rule matched)
NCT02276651	Observational Trial of a Therapeutic Platelet Transfusion Regimen	—	terminated	Oct 28, 2014	Klinikum Nürnberg	Insufficient recruitment	Enrollment / accrual
NCT00673153	Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated…	Phase 2	terminated	May 7, 2008	Fred Hutchinson Cancer Center	not stated	Not stated
NCT00708721	Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic…	Phase 1 / Phase 2	terminated	Jul 2, 2008	University of Utah	Data analysis revealed sufficient data for safety and efficacy	Safety / toxicity
NCT00589602	T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions…	Phase 2	terminated	Jan 9, 2008	The Cleveland Clinic	slow accrual	Enrollment / accrual
NCT02259348	Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following…	Phase 2	terminated	Oct 8, 2014	St. Jude Children's Research Hospital	Investigator's decision.	Investigator
NCT00450983	Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After…	Phase 2	terminated	Mar 22, 2007	Fred Hutchinson Cancer Center	not stated	Not stated
NCT00555048	Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in…	Phase 1 / Phase 2	terminated	Nov 7, 2007	Fred Hutchinson Cancer Center	Low accrual	Enrollment / accrual
NCT00863434	Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal…	Phase 2	terminated	Mar 18, 2009	University of Washington	not stated	Not stated
NCT00997243	Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic…	Phase 2	terminated	Oct 19, 2009	Alison Walker	Drug no longer being supplied by sponsor	Other (stated, no rule matched)
NCT00324324	Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem…	Phase 3	terminated	May 11, 2006	OHSU Knight Cancer Institute	not stated	Not stated
NCT00900068	Blood Samples From Patients on a Clinical Trial to CINV During HSCT	—	terminated	May 12, 2009	OHSU Knight Cancer Institute	not stated	Not stated
NCT01483274	Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem…(AML)	Phase 1	withdrawn	Dec 1, 2011	University of Louisville	Adult patient population barriers.	Other (stated, no rule matched)
NCT02564536	Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk…	Phase 1	withdrawn	Sep 30, 2015	Washington University School of Medicine	Lack of funding following full FDA clinical hold	Funding
NCT02791919	Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children,…	Phase 1	withdrawn	Jun 7, 2016	National Cancer Institute (NCI)	Other - Protocol moved to Disapproved	Other (stated, no rule matched)

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Feb 15, 2018source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules